The role of lactoferrin in the treatment of upper respiratory tract infections
DOI:
https://doi.org/10.12775/QS.2024.17.53395Keywords
lactoferrin, infections, viral infection, bacterial infection, upper respiratory tract infections, supplements, influenza, COVID-19Abstract
Introduction
Lactoferrin is a glycoprotein belonging to the group of transferrins found in most body fluids. It has been shown to possess antimicrobial, anti-inflammatory, immunomodulatory and anticancer properties. The increasing availability and widespread use of dietary supplements containing lactoferrin have been observed as supportive measures in managing various infections.
Aim of the study
The objective of this study is to summarize the current knowledge regarding the anti-infective - mostly antiviral - effects of lactoferrin and the justification for its use in the treatment of upper respiratory tract infections.
Knowledge summary
Scientific research has consistently confirmed the effectiveness of lactoferrin against pathogenic microorganisms. The antibacterial effect of this protein is based mainly on the management of available iron resources - an ingredient necessary for bacterial growth. On the other hand, the antiviral activity of this protein is based on the induction of interferon production.
Conclusion
Dietary supplements containing lactoferrin are approved by the US Food and Drug Administration (FDA) for supportive use in infections. Lactoferrin exhibits antimicrobial activity supported by research in specific infections. It has a good tolerance and safety profile, therefore it seems that it can be used adjunctively in this indication.
References
Cooke G, Valenti L, Glasziou P, Britt H. Common general practice presentations and publication frequency. Aust Fam Physician. 2013 Jan-Feb;42(1-2):65-8. PMID: 23529466
Lu Y, Tong J, Pei F, Yang Y, Xu D, Ji M, Xing C, Jia P, Xu C, Wang Y, Li G, Chai Z, Liu Y, Han J. Viral aetiology in adults with acute upper respiratory tract infection in Jinan, Northern China. Clin Dev Immunol. 2013;2013:869521. doi: 10.1155/2013/869521. Epub 2013 Apr 15. PMID: 23690828; PMCID: PMC3649347.
Xu Y, Wang Y, He J, Zhu W. Antibacterial properties of lactoferrin: A bibliometric analysis from 2000 to early 2022. Front Microbiol. 2022 Aug 17;13:947102. doi: 10.3389/fmicb.2022.947102. PMID: 36060777; PMCID: PMC9428516.
https://www.industryarc.com/Report/17805/lactoferrin-supplements-market.html
Jańczuk A, Brodziak A, Czernecki T, Król J. Lactoferrin-The Health-Promoting Properties and Contemporary Application with Genetic Aspects. Foods. 2022 Dec 23;12(1):70. doi: 10.3390/foods12010070. PMID: 36613286; PMCID: PMC9818722.
Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol. 2012 Jun;90(3):233-44. doi: 10.1139/o2012-016. Epub 2012 Apr 27. PMID: 22540735.
Soerensen M. Soerensen, SPL. The Proteins in Whey. C. R. Trav. Lab. Carlsberg, 23, 55-99, 1939.
Avalos-Gómez C, Ramírez-Rico G, Ruiz-Mazón L, Sicairos NL, Serrano-Luna J, de la Garza M. Lactoferrin: An Effective Weapon in the Battle Against Bacterial Infections. Curr Pharm Des. 2022;28(40):3243-3260. doi: 10.2174/1381612829666221025153216. PMID: 36284379.
Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005 Nov;62(22):2549-59. doi: 10.1007/s00018-005-5370-2. PMID: 16261255; PMCID: PMC7079806.
Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N, Saito T, Sekihara H. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol. 2002 Dec;17(12):1291-8. doi: 10.1046/j.1440-1746.2002.02868.x. PMID: 12423274.
Wakabayashi H, Takakura N, Yamauchi K, Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol. 2006 Feb;13(2):239-45. doi: 10.1128/CVI.13.2.239-245.2006. PMID: 16467332; PMCID: PMC1391931.
Drago-Serrano ME, Campos-Rodríguez R, Carrero JC, de la Garza M. Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections. Int J Mol Sci. 2017 Mar 1;18(3):501. doi: 10.3390/ijms18030501. PMID: 28257033; PMCID: PMC5372517.
Arnold D, Di Biase AM, Marchetti M, Pietrantoni A, Valenti P, Seganti L, Superti F. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res. 2002 Feb;53(2):153-8. doi: 10.1016/s0166-3542(01)00197-8. PMID: 11750941.
Redwan EM, Uversky VN, El-Fakharany EM, Al-Mehdar H. Potential lactoferrin activity against pathogenic viruses. C R Biol. 2014 Oct;337(10):581-95. doi: 10.1016/j.crvi.2014.08.003. Epub 2014 Sep 22. PMID: 25282173.
Grover M, Giouzeppos O, Schnagl RD, May JT. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acta Paediatr. 1997 Mar;86(3):315-6. doi: 10.1111/j.1651-2227.1997.tb08896.x. PMID: 9099323.
Portelli J, Gordon A, May JT. Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro. J Med Microbiol. 1998 Nov;47(11):1015-8. doi: 10.1099/00222615-47-11-1015. PMID: 9822301.
Sano H, Nagai K, Tsutsumi H, Kuroki Y. Lactoferrin and surfactant protein A exhibit distinct binding specificity to F protein and differently modulate respiratory syncytial virus infection. Eur J Immunol. 2003 Oct;33(10):2894-902. doi: 10.1002/eji.200324218. PMID: 14515273.
Gualdi L, Mertz S, Gomez AM, Ramilo O, Wittke A, Mejias A. Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model. Antiviral Res. 2013 Aug;99(2):188-95. doi: 10.1016/j.antiviral.2013.05.013. Epub 2013 Jun 2. PMID: 23735300.
Zuccotti GV, Trabattoni D, Morelli M, Borgonovo S, Schneider L, Clerici M. Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections. J Biol Regul Homeost Agents. 2009 Apr-Jun;23(2):119-23. PMID: 19589293.
Chen K, Chai L, Li H, Zhang Y, Xie HM, Shang J, Tian W, Yang P, Jiang AC. Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial. Nutrition. 2016 Feb;32(2):222-7. doi: 10.1016/j.nut.2015.08.010. Epub 2015 Sep 3. PMID: 26602290.
Shin K, Wakabayashi H, Yamauchi K, Teraguchi S, Tamura Y, Kurokawa M, Shiraki K. Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J Med Microbiol. 2005 Aug;54(Pt 8):717-723. doi: 10.1099/jmm.0.46018-0. PMID: 16014423.
Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P. Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. Sci Rep. 2017 Sep 6;7(1):10593. doi: 10.1038/s41598-017-10492-x. PMID: 28878220; PMCID: PMC5587682.
Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, Valenti P. Antiviral properties of lactoferrin--a natural immunity molecule. Molecules. 2011 Aug 16;16(8):6992-7018. doi: 10.3390/molecules16086992. PMID: 21847071; PMCID: PMC6264778.
Denani CB, Real-Hohn A, de Carvalho CAM, Gomes AMO, Gonçalves RB. Lactoferrin affects rhinovirus B-14 entry into H1-HeLa cells. Arch Virol. 2021 Apr;166(4):1203-1211. doi: 10.1007/s00705-021-04993-4. Epub 2021 Feb 19. PMID: 33606112; PMCID: PMC7894240.
Alves NS, Azevedo AS, Dias BM, Horbach IS, Setatino BP, Denani CB, Schwarcz WD, Lima SMB, Missailidis S, Ano Bom APD, Silva AMV, Barreto Vieira DF, Silva MAN, Barros CA, Carvalho CAM, Gonçalves RB. Inhibition of SARS-CoV-2 Infection in Vero Cells by Bovine Lactoferrin under Different Iron-Saturation States. Pharmaceuticals (Basel). 2023 Sep 25;16(10):1352. doi: 10.3390/ph16101352. PMID: 37895823; PMCID: PMC10609673.
He ST, Qin H, Guan L, Liu K, Hong B, Zhang X, Lou F, Li M, Lin W, Chen Y, He C, Liu F, Lu S, Luo S, Zhu S, An X, Song L, Fan H, Tong Y. Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model. J Med Virol. 2023 Jan;95(1):e28281. doi: 10.1002/jmv.28281. PMID: 36329614; PMCID: PMC9878033.
Navarro R, Paredes JL, Tucto L, Medina C, Angles-Yanqui E, Nario JC, Ruiz-Cabrejos J, Quintana JL, Turpo-Espinoza K, Mejia-Cordero F, Aphang-Lam M, Florez J, Carrasco-Escobar G, Ochoa TJ. Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID). Biometals. 2023 Jun;36(3):463-472. doi: 10.1007/s10534-022-00477-3. Epub 2022 Dec 7. PMID: 36474100; PMCID: PMC9735051.
Matino E, Tavella E, Rizzi M, Avanzi GC, Azzolina D, Battaglia A, Becco P, Bellan M, Bertinieri G, Bertoletti M, Casciaro GF, Castello LM, Colageo U, Colangelo D, Comolli D, Costanzo M, Croce A, D'Onghia D, Della Corte F, De Mitri L, Dodaro V, Givone F, Gravina A, Grillenzoni L, Gusmaroli G, Landi R, Lingua A, Manzoni R, Marinoni V, Masturzo B, Minisini R, Morello M, Nelva A, Ortone E, Paolella R, Patti G, Pedrinelli A, Pirisi M, Ravizzi L, Rizzi E, Sola D, Sola M, Tonello N, Tonello S, Topazzo G, Tua A, Valenti P, Vaschetto R, Vassia V, Zecca E, Zublena N, Manzoni P, Sainaghi PP. Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial. Nutrients. 2023 Mar 4;15(5):1285. doi: 10.3390/nu15051285. PMID: 36904283; PMCID: PMC10005739.
Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005 Jul;67(1):31-7. doi: 10.1016/j.antiviral.2005.03.005. PMID: 15916817.
Kaczyńska K, Jampolska M, Wojciechowski P, Sulejczak D, Andrzejewski K, Zając D. Potential of Lactoferrin in the Treatment of Lung Diseases. Pharmaceuticals (Basel). 2023 Jan 28;16(2):192. doi: 10.3390/ph16020192. PMID: 37259341; PMCID: PMC9960651.
Yen MH, Chiu CH, Huang YC, Lin TY. Effects of lactoferrin-containing formula in the prevention of enterovirus and rotavirus infection and impact on serum cytokine levels: a randomized trial. Chang Gung Med J. 2011 Jul-Aug;34(4):395-402. PMID: 21880194.
Tang J, Chen J, He T, Jiang Z, Zhou J, Hu B, Yang S. Diversity of upper respiratory tract infections and prevalence of Streptococcus pneumoniae colonization among patients with fever and flu-like symptoms. BMC Infect Dis. 2019 Jan 7;19(1):24. doi: 10.1186/s12879-018-3662-z. PMID: 30616564; PMCID: PMC6323860.
Dasaraju PV, Liu C. Infections of the Respiratory System. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 93.
Angulo-Zamudio UA, Vidal JE, Nazmi K, Bolscher JGM, Leon-Sicairos C, Antezana BS, Canizalez-Roman A, León-Sicairos N. Lactoferrin Disaggregates Pneumococcal Biofilms and Inhibits Acquisition of Resistance Through Its DNase Activity. Front Microbiol. 2019 Oct 18;10:2386. doi: 10.3389/fmicb.2019.02386. PMID: 31681240; PMCID: PMC6813537.
Kosznik-Kwaśnicka K, Kaźmierczak N, Piechowicz L. Activity of Phage-Lactoferrin Mixture against Multi Drug Resistant Staphylococcus aureus Biofilms. Antibiotics (Basel). 2022 Sep 16;11(9):1256. doi: 10.3390/antibiotics11091256. PMID: 36140035; PMCID: PMC9495459.
Petitclerc D, Lauzon K, Cochu A, Ster C, Diarra MS, Lacasse P. Efficacy of a lactoferrin-penicillin combination to treat {beta}-lactam-resistant Staphylococcus aureus mastitis. J Dairy Sci. 2007 Jun;90(6):2778-87. doi: 10.3168/jds.2006-598. PMID: 17517718.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marlena Cąkała, Magdalena Kozioł, Karolina Błaszczak, Kamila Podgórniak, Julia Piotrowska, Joanna Skotnicka, Aleksandra Zajkowska, Maria Witkowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 103
Number of citations: 0
